| Indication | polycythemia vera |
| Drug | rusfertide |
| Mechanism of Action | hepcidin mimetic |
| Company | Zealand Pharma |
| Category | Corporate & Strategic |
| Sub Category | Divestiture / Asset Sale |
| Therapeutic Area | Hematology |
| Deal Value | USD 100 million |
| Acquiring Company | Royalty Pharma plc |
| Upfront Payment | USD 50 million |
| Deferred Payment | USD 50 million (due on first anniversary) |
| Royalty Rate (initial) | 1% |
| Royalty Rate (above $1.5B sales) | Zealand Pharma retains 0.25%, Royalty Pharma retains 0.75% |
| PDUFA Goal Date | Third quarter of 2026 |
| Regulatory Agency | U.S. FDA |
| Commercialization Partner | Takeda |
| Closing Date | August 12, 2026 |
Zealand Pharma Sells Rusfertide Royalty Rights to Royalty Pharma
Zealand Pharma has entered into a royalty purchase and sale agreement with Royalty Pharma, divesting its economic interests in rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera. The deal is valued at USD 100 million, comprising an upfront payment of USD 50 million and a further USD 50 million due on the first anniversary. This strategic move allows Zealand Pharma to convert a future royalty stream into immediate capital, which will be redeployed to support its core strategic priorities in metabolic health.
- Financial Structure of the Agreement: Zealand Pharma will receive a total of USD 100 million from Royalty Pharma for the sale of its economic interests related to rusfertide. This includes an immediate upfront payment of USD 50 million upon the transaction's closing, with the remaining USD 50 million scheduled for payment on the first anniversary of the agreement.
- Royalty Rights and Future Sales: The agreement transfers rights to a one percent royalty on potential future global net sales of rusfertide, alongside regulatory and commercial milestones. Notably, Zealand Pharma retains a 0.25% royalty on annual net global sales exceeding USD 1.5 billion, while Royalty Pharma will hold a 0.75% royalty on sales above this threshold.
- Strategic Capital Redeployment: This transaction is a strategic financial move for Zealand Pharma, enabling the company to unlock immediate capital from a non-core royalty entitlement. The proceeds will be redeployed to fund key strategic priorities and growth opportunities, aligning with its "Metabolic Frontier 2030" strategy focused on advancing medicines for obesity and metabolic health.
- Rusfertide's Regulatory Status and Commercialization: Rusfertide, an investigational hepcidin mimetic for polycythemia vera, is currently under regulatory review. The U.S. FDA has set a Prescription Drug User Fee Act (PDUFA) goal date for its New Drug Application (NDA) in the third quarter of 2026, with Takeda responsible for the global commercialization of the drug.
Assessing Rusfertide's Safety and Tolerability Profile
Published clinical data consistently demonstrate a favorable safety and tolerability profile for rusfertide across both healthy volunteer studies and patients with polycythemia vera (PV). Adverse events have been predominantly mild-to-moderate in severity, with no clinically significant systemic signals identified to date.
No serious adverse events in healthy volunteer studies: Across first-in-human studies evaluating single and repeated subcutaneous doses (1–80 mg), no serious or severe treatment-emergent adverse events (TEAEs) were reported, and no clinically meaningful abnormalities were observed in laboratory parameters, vital signs, or electrocardiograms.
Injection-site reactions as the predominant TEAE class: Across multiple healthy volunteer studies — including lyophilized formulation cohorts (10–60 mg) and a five-week multiple-dose study (60 mg once weekly) — the most frequently reported treatment-related events were injection-site erythema, pruritus, and induration, all of which were mild in severity.
No cardiac or QTc liability identified: A dedicated thorough QT study with rusfertide 90 mg in healthy adults confirmed no clinically relevant effects on heart rate, cardiac conduction, or QTc interval. TEAEs in ≥5% of subjects included headache, nausea, injection-site erythema, injection-site pain, and influenza-like illness, all rated mild.
Well tolerated in PV patients with low rates of severe events: In the Phase 2 REVIVE trial (Parts 1 and 2), Grade 3 adverse events occurred in 13% of patients, with no Grade 4 or 5 events reported. Injection-site reactions were common but limited to Grade 1 or 2 severity.
Broad tolerability confirmed in an open-label PV cohort: In a separate open-label Phase 2 study of suboptimally controlled PV patients, 85% of patients (17/20) experienced TEAEs, the majority of which were Grade 1 or 2, supporting rusfertide's tolerability in a clinically relevant, real-world-proximate population.
Addressing Unmet Needs in Polycythemia Vera: A Shifting Landscape
The therapeutic landscape for polycythemia vera (PV) is evolving beyond hematocrit control toward disease modification, molecular remission, and improved long-term survival outcomes. Over the past three years, several distinct unmet needs and target populations have emerged as focal points for clinical development and strategic investment.
Disease modification and progression prevention: Current therapeutic strategies cannot delay PV progression, driving demand for next-generation agents capable of slowing disease course and improving survival—not merely managing symptoms.
Hydroxyurea (HU)-resistant and intolerant patients: Approximately 15–24% of PV patients develop resistance to or intolerance of HU, leading to increased morbidity and an urgent need for alternative cytoreductive options. Ruxolitinib is approved as a second-line agent in this setting, yet the population remains a primary focus for further therapeutic development.
Phlebotomy-dependent patients: Patients requiring ongoing phlebotomy during HU treatment represent a high-risk subgroup associated with early disease progression and elevated thromboembolic complications. Hepcidin mimetics have emerged as a promising class in this space, offering a mechanism to restore iron homeostasis and achieve phlebotomy independence.
Patients with suboptimal molecular responses: Emerging data with interferon-α, ruxolitinib, and combination regimens suggest the potential for molecular remission in a subset of patients; however, long-term follow-up is still needed to establish the correlation between molecular response and clinically meaningful endpoints such as progression-free and thrombosis-free survival.
Thrombosis risk reduction: Improved thrombosis-free survival remains a critical and incompletely addressed goal, with stricter hematocrit control enabled by hepcidin mimetics positioned as a potential pathway to meaningfully reduce thromboembolic events.
Frequently Asked Questions
References
- [1] Modi NB, Shames R et al.. Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study. European journal of haematology. 2024 Sep. 38785334
- [2] Kremyanskaya M, Kuykendall AT et al.. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. The New England journal of medicine. 2024 Feb 22. 38381675
- [3] Modi NB, Khanna S et al.. Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers. Drugs in R&D. 2024 Dec. 39546273
- [4] Modi NB, Dinh P et al.. Evaluation of Rusfertide, a Hepcidin Mimetic, on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT Study in Healthy Participants. Clinical therapeutics. 2025 Nov. 41033871
- [5] Modi NB, Dinh P et al.. Multiple-Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous Rusfertide, a Hepcidin Mimetic, in Healthy Subjects. Clinical pharmacology in drug development. 2025 Apr. 39888264
- [6] Chew LP, Ginzburg YZ et al.. Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera. Leukemia research. 2025 Dec. 41175501
- [7] Chojecki A, Boselli D et al.. Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice. Annals of hematology. 2024 Aug. 38662203
- [8] Heidel FH, De Stefano V et al.. Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM). Leukemia. 2025 Jul. 40281326
- [9] Harrison CN, Kiladjian JJ et al.. Ruxolitinib treatment in patients with polycythemia vera reduces JAK2 variant allele frequency and improves symptom burden and hematocrit control. Therapeutic advances in hematology. 2026. 41890273
- [10] Tefferi A, Vannucchi AM et al.. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. American journal of hematology. 2024 Apr. 38269572
- [11] Waksal JA, Wagner NE et al.. Risk factors for disease progression and treatment goals in polycythemia vera. Clinical advances in hematology & oncology : H&O. 2024 Jan-Feb. 38294739
- [12] Kirito K. [Novel treatment strategies for polycythemia vera: focus on ropeginterferon alfa-2b]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2025. 40350277
- [13] Nada EA, Elfagieh MA et al.. Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis. Annals of hematology. 2025 Dec. 41238945
- [14] Martinez J, Handa S et al.. The evolving landscape of polycythemia vera therapies. Expert opinion on pharmacotherapy. 2024 Aug. 39106053
- [15] Theocharides A, Gisslinger H et al.. Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study. European journal of haematology. 2024 Mar. 37899734
- [16] Ümit EG, Baysal M et al.. Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms with Relation to Genetic Burden and Thrombosis. Turkish journal of haematology : official journal of Turkish Society of Haematology. 2024 Aug 28. 38801033
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
